Potential Benefits

• Helps With Neuropathy Pain
• Reduces Inflammation
• Protects Cells From Stress

ARA-290, generically known as cibinetide, is a synthetic 11-amino-acid peptide that activates the innate repair receptor (IRR), delivering anti-inflammatory and tissue-repair signaling without stimulating red blood cell production. Cibinetide holds FDA Orphan Drug and Fast Track designations for sarcoidosis-related neuropathic pain, and EU Orphan Drug status.

Reduces Neuropathy Pain

In clinical trials, ARA-290 produced significant, sustained improvements on validated neuropathic symptom scales in both sarcoidosis-related and type 2 diabetic small fiber neuropathy patients.

Promotes Small-Fiber Nerve Regeneration

Studies showed measurable, placebo-corrected increases in corneal nerve fiber density and area, a direct biomarker of peripheral nerve repair.

Anti-inflammatory

ARA-290 can protect against local inflammatory and ischemic injury signaling across neural, retinal, and vascular tissue.

Avoids Common Side Effects

ARA-290 doesn’t promote red blood cell increases, a common unwanted side effect of other treatments.

Considerations

ARA-290 shows favorable safety signals, although the clinical studies are small. It should be used only under close supervision.

Call To Action:

Wondering if you’re a candidate for ARA-290? Schedule a consultation with BeautiPharm staff,
who can provide you with a thorough evaluation.